Sign in
Taking people in South AfricaPhase 1

Tests the RNA-based vaccine BNT168 in adults with or without HIV

Tests an experimental RNA vaccine, BNT168, in adults with or without HIV.

Key facts

Who runs it
BioNTech SE
Where
Johannesburg, South AfricaSee the 3 sitesAlso in 1 other country, 1 site
Trial code
Registry title
A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV
Status
Recruiting
Phase
Phase 1
People taking part
126 people, planned
Started
4 Aug 2026
Expected to end
Feb 2028
Type of study
Interventional, 7 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • BNT168
  • Placebo
Record updated
14 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy adults aged 18 to 50, either living with HIV or without HIV, to test the RNA vaccine BNT168.

Age
18 to 50 years
Sex
All sexes
Disease stage
Adults without HIV (HIV-1 and HIV-2 negative), or adults living with HIV-1 (HIV-2 negative). Overall healthy as defined in the protocol.
Earlier treatment
No earlier HIV vaccine or HIV broadly neutralizing antibody in another study. For people living with HIV: stable continuous cART for at least 12 months, no change in its components for at least 12 weeks, and willing to stop cART and restart it when needed. They must never have received lenacapavir and have had no other long-acting antiretroviral therapy in the last 2 years.
Biomarker or test result
For people living with HIV: CD4+ T cell count of ≥500 cells/µL and plasma HIV-1 RNA below 50 cps/mL for at least 6 months. For people without HIV: negative HIV-1 and HIV-2 tests.

Main reasons for not taking part

  • Heart disease, such as myocarditis, heart attack or heart failure
  • Diabetes, or taking any medicine for diabetes
  • Weak or changed immune function, or taking immune-suppressing medicine, other than HIV
  • History of opportunistic infections or AIDS-defining illnesses (people living with HIV)
  • Serious reaction to a vaccine or its components in the past

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Are 18 to 50 years of age inclusive at the time of giving informed consent
  • For PLWOH: Individuals who are HIV-1 and HIV-2 negative at Visit 0. For PLWH: Individuals who are HIV-1 positive and HIV-2 negative at Visit 0
  • Have not received an HIV vaccination or HIV broadly neutralizing antibody in another clinical study
  • Are overall healthy as defined in the protocol
  • Individuals who have screening hematology and/or blood chemistry laboratory values as defined in the protocol
  • For PLWOH, starting at Visit 0 and continuously until the last planned visit in this study, individuals who:; Are assessed by the investigator as having a low likelihood of acquiring HIV and are committed to avoiding behaviors associated with a higher likelihood of acquiring HIV until the End of Study Visit; Agree to discuss HIV disease risks; Agree to HIV infection risk reduction counseling
  • For PLWH, individuals who:; Have been on stable continuous cART for at least 12 months (defined as no interruptions longer than 14 continuous days) and with no changes in the components of the cART for at least 12 weeks prior to Visit 1; Are not on a non-nucleoside reverse transcriptase inhibitor at screening; Have never received lenacapavir and have not received other long-acting antiretroviral therapies in the last 2 years (i.e., intramuscular cabotegravir, cabotegravir-rilpivirine); Are willing to undergo HIV transmission risk reduction counseling and to maintain low-risk behavior to protect their partners; Have a CD4+ T cell count of ≥500 cells/µL at Visit 0; Per medical history, any available prior CD4+ T cell count must be ≥350 cells/µL; Have plasma HIV-1 RNA levels of <50 cps/mL for ≥6 months prior to study entry per investigator review of records and/or participant history (single measurements of <200 cps/mL are allowed if preceded and followed by values of <50 cps/mL); Are willing to stop cART and undergo ATI at the timepoint defined in the protocol; Are willing to re-initiate cART upon meeting cART restart criteria; Site investigator anticipates that a fully active alternative cART regimen could be constructed and would be available in the event of virologic failure on the participant's current cART regimen
  • Agree not to donate blood from the time of first IMP administration until 90 days after the last IMP administration for PLWOH and until the End of Study Visit for PLWH

Who cannot take part

  • Have had major surgery (e.g., major cardiopulmonary or abdominal operations) as per the investigator's judgment within 4 weeks before Visit 0, or will not have fully recovered from surgery, or have major surgery planned during the time the participants are expected to participate in the study
  • Have any current febrile illness (body temperature >38.0°C/>100.4°F) or other acute illness within 48 hours prior to IMP administration
  • Have a known or suspected impairment/alteration of immune function, autoimmune disease, or immunodeficiency (except HIV for PLWH), including receipt of any immunostimulant, immunomodulator, immunosuppressive medication, immunoglobulin, or blood/plasma product within 60 days prior to Visit 1 or planned administration during the study. Use of inhaled, intranasal, topical, or locally injected corticosteroids (e.g., intraarticular or intrabursal administration) is acceptable
  • Have received any live vaccines within 28 days prior to Visit 0 or any other vaccines within 14 days prior to Visit 0 or who are planning to receive any vaccine within 28 days of each IMP dose. When possible, standard of care vaccinations should be planned with the study interventions in mind
  • Have any existing condition which may affect IMP injection and/or assessment of local reactions, e.g., tattoos, severe scars, etc
  • Have any bleeding diathesis or condition associated with prolonged bleeding that, in the opinion of the investigator, could compromise their wellbeing if they participate in the study
  • Have any current or history of cardiovascular diseases, e.g., myocarditis, pericarditis, myocardial infarction, congestive heart failure, cardiomyopathy or clinically significant arrhythmias, or any clinically significant cardiac disease per the investigator's judgment
  • Have Grade ≥2 hypertension per Food and Drug Administration toxicity grading scale at screening
  • Have a history of malignancy within 5 years before screening. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or a malignancy which is considered in the investigator's judgment to have minimal risk of recurrence. Any malignancy that is an AIDS-defining illness per protocol is exclusionary regardless of perceived risk of recurrence
  • For PLWH: Have a history of opportunistic infections and/or AIDS-defining illnesses according to the US Centers for Disease Control and Prevention 2014 and the National Institutes of Health 2024
  • For PLWOH: Have current untreated or incompletely treated active tuberculosis infection (by history or concerning symptoms). For PLWH: Have current untreated or incompletely treated active tuberculosis infection (by history or concerning symptoms or sputum molecular testing) or current latent tuberculosis infection (by blood interferon-gamma release assay [IGRA]). Not excluded: Participants who have a positive IGRA but were fully treated for latent or active tuberculosis infection, per history, review of available records, and per investigator discretion
  • For PLWH: Have untreated or incompletely treated syphilis or genital, oropharyngeal or rectal gonorrhea or chlamydia infection
  • For PLWH: Have a history of multi-class drug resistant HIV-1 infection defined as resistance to three or more classes of HIV drugs
  • History of any serious adverse reactions (including anaphylaxis, respiratory distress, angioedema, or urticaria) to vaccines or to vaccine components such as lipids
  • Have a history of progressive or severe neurologic disorder, seizure disorder, or Guillain-Barré syndrome
  • Have an estimated glomerular filtration rate of <45 mL/min/1.73 m2 using the 2021 chronic kidney disease epidemiology creatinine equation
  • Have a history of diabetes mellitus type 1 or type 2, a screening hemoglobin A1c ≥6.5%, or are taking any medication for treatment of diabetes. (Not excluded: A history of isolated gestational diabetes.); NOTE: Other protocol defined Inclusion/Exclusion criteria apply
  • Have an abnormal electrocardiogram at Visit 0 as specified in the protocol

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 50 years old?

This trial is currently available in South Africa.

Also in 1 other country, 1 site

  • Clinical HIV Research Unit (CHRU)Johannesburg, South AfricaTaking people
  • Perinatal HIV Research Unit (PHRU)Johannesburg, South AfricaNot yet recruiting
  • Wits RHI - Shandukani ResearchJohannesburg, South AfricaTaking people

About the trial

What the trial wants to find out

This study will test a new ribonucleic acid (RNA)-based vaccine called BNT168 in adults living both with and without human immunodeficiency virus (HIV), to see how safe it is, how well it triggers the body's immune response and how it affects the amount of virus in the body.

The 7 groups in the trial

  • A1 in PLWOH - BNT168 dose level 1Treatment being tested

    Treatment: BNT168

  • A2 in PLWOH - BNT168 dose level 2Treatment being tested

    Treatment: BNT168

  • A3 in PLWOH - BNT168 dose level 3Treatment being tested

    Treatment: BNT168

  • A4 in PLWH - BNT168 dose level 2Treatment being tested

    This cohort will undergo ATI post vaccination

    Treatment: BNT168

  • A5 in PLWH - BNT168 dose level 3Treatment being tested

    This cohort will undergo ATI post vaccination

    Treatment: BNT168

  • PLWOH - PlaceboPlacebo, for comparison

    Treatment: Placebo

  • PLWH - PlaceboPlacebo, for comparison

    PLWH participants receiving placebo will also undergo ATI post vaccination

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Placebo-controlled, Phase I/II Clinical Trial to Evaluate the Safety, Immunogenicity, and Impact on Virological Control of the Investigational RNA-based Vaccine BNT168 in Adults Living With or Without HIV
Plain-language title
Tests the RNA-based vaccine BNT168 in adults with or without HIVGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT07698600, who can take part
Record updated
14 October 2026